Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 9/20 | 0.84 |
| ▸ | LMNA | P02545 | 9/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.84 |
| ▸ | MAPT | P10636 | 6/20 | 0.84 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.84 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.84 |
| ▸ | SHBG | P04278 | 4/20 | 0.84 |
| ▸ | SERPINA6 | P08185 | 4/20 | 0.84 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.84 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.84 |
| ▸ | TSHR | P16473 | 5/20 | 0.78 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.78 |
| ▸ | PGR | P06401 | 5/20 | 0.78 |
| ▸ | AR | P10275 | 4/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.78 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.78 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.78 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.78 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.78 |
| ▸ | MEN1 | O00255 | 2/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25933805 | 1.00 | CYP3A4 (0.84) | CYP3A4LMNAALDH1A1MAPTSMN1; SMN2 | |
| Desoxycorticosterone SCHEMBL25773308 | 0.91 | LMNA (1.00) | CYP3A4LMNAALDH1A1MAPTSMN1; SMN2 | |
| Desoxycorticosterone SCHEMBL4065 | 0.91 | LMNA (1.00) | CYP3A4LMNAALDH1A1MAPTSMN1; SMN2 | |
| Desoxycorticosterone SCHEMBL28269906 | 0.91 | LMNA (1.00) | CYP3A4LMNAALDH1A1MAPTSMN1; SMN2 | |
| Desoxycorticosterone SCHEMBL13752803 | 0.91 | LMNA (1.00) | CYP3A4LMNAALDH1A1MAPTSMN1; SMN2 | |
| Desoxycorticosterone SCHEMBL15763287 | 0.91 | LMNA (1.00) | CYP3A4LMNAALDH1A1MAPTSMN1; SMN2 | |
| Desoxycorticosterone SCHEMBL18891475 | 0.91 | LMNA (1.00) | CYP3A4LMNAALDH1A1MAPTSMN1; SMN2 | |
| Desoxycorticosterone SCHEMBL21243062 | 0.91 | LMNA (1.00) | CYP3A4LMNAALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL22732246 | 0.91 | LMNA (0.84) | CYP3A4LMNAALDH1A1MAPTSMN1; SMN2 | |
| Desoxycorticosterone SCHEMBL4066 | 0.91 | LMNA (1.00) | CYP3A4LMNAALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0127294-B1 | STEROID DEHYDROGENATION | THE UPJOHN COMPANY (US) | 1986-12-17 | — | — | EP | claimed |
| EP-2348030-B1 | 17-Alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as antiprogestational agents | US GOV HEALTH & HUMAN SERV (US) | 2015-05-06 | — | — | EP | disclosed |
| US-20140107089-A1 | STRUCTURAL MODIFICATION OF 19-NORPROGESTERONE I: 17-ALPHA-SUBSTITUTED-11-BETA-SUBSTITUTED-4-ARYL AND 21-SUBSTITUTED 19-NORPREGNADIENEDIONE AS NEW ANTIPROGESTATIONAL AGENTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2014-04-17 | — | — | US | disclosed |
| US-8569276-B2 | Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2013-10-29 | — | — | US | disclosed |
| US-8003629-B2 | 21-substituted progesterone derivatives as new antiprogestational agents | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-08-23 | — | — | US | disclosed |
| EP-2348031-A2 | 17-Alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as antiprogestational agents | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services (US) | 2011-07-27 | — | — | EP | disclosed |
| EP-2348030-A2 | 17-Alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as antiprogestational agents | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services (US) | 2011-07-27 | — | — | EP | disclosed |
| US-7759330-B2 | 21-substituted progesterone derivatives as new antiprogestational agents | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-07-20 | — | — | US | disclosed |
| US-20100113408-A1 | 21-SUBSTITUTED PROGESTERONE DERIVATIVES AS NEW ANTIPROGESTATIONAL AGENTS | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2010-05-06 | — | — | US | disclosed |
| EP-2033965-A2 | 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as antiprogestational agents | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services (US) | 2009-03-11 | — | — | EP | disclosed |
| US-20010044431-A1 | Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium | NEW LIFE PHARMACEUTICALS INC. | 2001-11-22 | — | — | US | disclosed |
| WO-2001074840-A2 | 17-ALPHA-SUBSTITUTED-11-BETA-SUBSTITUTED-4-ARYL AND 21-SUBSTITUTED 19-NORPREGNA 21-SUBSTITUTED 19-NORPREGNADIENEDIONE AS ANTIPROGESTATIONAL AGENTS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES (US) | 2001-10-11 | — | — | WO | disclosed |
| EP-0900234-B1 | 21-SUBSTITUTED PROGESTERONE DERIVATIVES AS NEW ANTIPROGESTATIONAL AGENTS | US GOV HEALTH & HUMAN SERV (US) | 2000-07-05 | — | — | EP | disclosed |
| EP-0900234-A1 | 21-SUBSTITUTED PROGESTERONE DERIVATIVES AS NEW ANTIPROGESTATIONAL AGENTS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-03-10 | — | — | EP | disclosed |
| US-5770227-A | Progesterone replacement therapy | ALZA CORPORATION (US) | 1998-06-23 | — | — | US | disclosed |
| WO-1997041145-A1 | 21-SUBSTITUTED PROGESTERONE DERIVATIVES AS NEW ANTIPROGESTATIONAL AGENTS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-11-06 | — | — | WO | disclosed |
| US-5633011-A | Progesterone replacement therapy | ALZA CORPORATION (US) | 1997-05-27 | — | — | US | disclosed |
| US-5620705-A | Progestin tablet | ALZA CORPORATION (US) | 1997-04-15 | — | — | US | disclosed |
| EP-0280797-B1 | MEDICAMENTS FOR TREATMENT OF OCULAR INFLAMMATION | ALCON LABORATORIES, INC. (US) | 1992-08-26 | — | — | EP | disclosed |
| EP-0054786-B1 | 6-ALPHA-METHYL HYDROCORTISONE DERIVATIVES, THEIR PREPARATION AND THEIR UTILIZATION | SCHERING AKTIENGESELLSCHAFT (DE) | 1985-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107089-A1 | STRUCTURAL MODIFICATION OF 19-NORPROGESTERONE I: 17-ALPHA-SUBSTITUTED-11-BETA-SUBSTITUTED-4-ARYL AND 21-SUBSTITUTED 19-NORPREGNADIENEDIONE AS NEW ANTIPROGESTATIONAL AGENTS | CYP19A1, HSD17B11, CYP17A1 | CYP3A4 354/4885LMNA 275/4885ALDH1A1 720/4885 |
| US-20100113408-A1 | 21-SUBSTITUTED PROGESTERONE DERIVATIVES AS NEW ANTIPROGESTATIONAL AGENTS | HSD17B11, NR5A1, HSD17B3 | CYP3A4 175/4885LMNA 2696/4885ALDH1A1 1761/4885 |
| US-20010044431-A1 | Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium | HDGF, PGF, OGFRL1 | CYP3A4 4688/4885LMNA 3753/4885ALDH1A1 929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.